A practical reference on immunomodulator: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-07-14. Anything still debated is marked as such rather than presented as settled.
Laboratory work indicates that the peptide acts on cells of both the innate and adaptive immune systems. Reported effects include signalling through Toll-like receptors on dendritic cells, enhanced T-cell maturation, and increased natural killer cell activity. These actions are described largely from cell-culture and animal experiments, and the precise receptor-level events remain incompletely defined. Studies in humans have generally measured immune markers rather than a single defined molecular target. The resulting picture remains partly descriptive.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Results across trials have been mixed, and several studies were small or conducted under differing protocols. Regulatory status varies by country, and the compound is not approved in every jurisdiction where it is studied. Evidence for any single indication should be read with attention to sample size and endpoint choice.
Quantifying thymosin alpha-1 in a sample usually relies on reverse-phase high-performance liquid chromatography. The peptide lacks strong chromophores, so detection often occurs at 214 nm, where the peptide backbone absorbs. Mass spectrometry provides confirmatory identification and can detect sequence variants or truncations. Immunoassays have been used in biological matrices, but they may cross-react with related fragments. For purity assessment, chromatographic peak area gives the main component percentage, while mass accuracy verifies molecular identity.
The lyophilized peptide is generally stable for extended periods when kept cold and dry. Once dissolved, aqueous solutions are less stable; hydrolysis, oxidation, and aggregation can degrade the material. Storage at -20 °C or lower slows these processes. Repeated freeze-thaw cycles are best avoided because they can promote aggregation. The exact shelf life depends on formulation, pH, and concentration, so stability studies are typically performed for each specific product.
Quality control for thymosin alpha-1 focuses on identity, purity, and potency. Identity is confirmed by mass spectrometry and amino acid analysis, while purity is assessed by chromatography with limits on related substances and residual solvents. Potency assays may use cell-based immune readouts, but these are not standardized across laboratories. Regulatory status differs by jurisdiction; no product is approved in the United States for clinical use, whereas some other countries register injectable forms for specific indications.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Peptide | 28 amino acid residues |
| Molecular weight | Approximately 3108 Da | Depends on acetylation state |
| N-terminal modification | Acetylated | Affects charge and stability |
| Natural source | Fragment of thymosin beta-4 | Cleaved in vivo |
| Sequence length | 28 residues | Synthetic form matches natural |
Thymosin alpha 1 was identified in 1977 as a component of thymosin fraction 5, a heterogeneous preparation used in early studies of thymic function. Investigators purified the active material and determined its amino acid sequence, which enabled chemical synthesis. Work in the following decades concentrated on T-cell maturation and immune reconstitution in animals and small human cohorts. Early preparations varied in composition, so results from that period are difficult to compare with studies using defined synthetic peptide.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Findings across trials are mixed; some report changes in selected immune markers, while others find no clear clinical benefit. Many studies are small and define outcomes differently, which limits comparison. Regulatory approval is confined to a few countries, and the compound is not an approved drug in the United States or most of Europe.
Overall evidence quality varies considerably. A large share of published reports come from single centers, rely on surrogate immunological markers, or lack adequate control groups. Systematic reviews have highlighted this heterogeneity as a barrier to pooling results. Open questions include which patients, if any, might benefit, what treatment duration is appropriate, and whether any effect is independent of standard care. The peptide is often described as an immune modulator rather than a therapy for one disease, which complicates confirmatory trial design.
Several names appear in the literature for this peptide, including thymalfasin and the abbreviation T-alpha-1. Naming conventions differ among research articles, regulatory documents, and supplier catalogs, which complicates literature searches. Both synthetic and recombinant production routes yield a peptide with the same 28-residue sequence as the thymic isolate. Because the thymosin label also covers unrelated peptides, sources should be compared by sequence rather than by name alone.
The peptide occurs naturally in thymic tissue and has been detected in serum and other biological fluids. Reported concentrations are low, and reliable measurement generally requires immunoassay or mass spectrometry with an enrichment step. It is released from a larger precursor, prothymosin alpha, by proteolytic cleavage, although the enzymes involved are not fully characterized. Whether circulating levels reflect thymic output specifically remains an open question.
The first cycle is a way of synthesis of glyoxylate. During this cycle, two equivalents of bicarbonate are fixed by the action of two enzymes: the acetyl-CoA carboxylase catalyzes the carboxylation of the acetyl-CoA to malonyl-CoA and propionyl-CoA carboxylase catalyses the carboxylation of propionyl-CoA to methylamalonyl-CoA. From this point, a series of reactions lead to the formation of glyoxylate, which will thus become part of the second cycle.
Lining mucosa, nonkeratinized stratified squamous epithelium, found almost everywhere else in the oral cavity, including the: Alveolar mucosa, the lining between the buccal and labial mucosae. It is a brighter red, smooth, and shiny with many blood vessels, and is not connected to underlying tissue by rete pegs. Buccal mucosa, the inside lining of the cheeks; part of the lining mucosa. Labial mucosa, the inside lining of the lips; part of the lining mucosa. Masticatory mucosa, keratinized stratified squamous epithelium, found on the dorsum of the tongue, hard palate, and attached gingiva. Specialized mucosa, specifically in the regions of the taste buds on lingual papillae on the dorsal surface of the tongue; contains nerve endings for general sensory reception and taste perception.
==== Creatine ==== One of the most popular supplements is creatine. Although the body naturally produces creatine, it typically only produces enough to maintain around 60–80% of its full capacity. Creatine is most often found in red meats and seafood; however, a pound of uncooked beef and salmon only contains 1–2 grams of creatine. About 95% of creatine is stored in the skeletal muscle, while the remaining percentage is found in the brain and testes. Typical supplemental creatine doses are 3–5 grams per day. While taking creatine as a dietary supplement doesn't directly build muscle, it can lead to rapid energy production, increase improvement, enhance muscle recovery, prevent injuries, and provide neuroprotection. This is due to the fact that when creatine is paired with increased glycogen storage in the muscle, glycogen can quickly release glucose, providing an immense burst of energy. This burst of energy is helpful for professional bodybuilders, as anabolic steroids often cause fatigue and other health issues over time.
Sources: en.wikipedia.org
The official name of the country, according to the constitution adopted concurrently with the UDI in November 1965, was Rhodesia, which derives from Cecil Rhodes. This was not the case under British law, however, which considered the territory's legal name to be Southern Rhodesia, the name given to the country in 1898 during the British South Africa Company's administration of the Rhodesias, and retained by the self-governing colony of Southern Rhodesia after the end of company rule in 1923. This naming dispute dated back to October 1964, when Northern Rhodesia became independent from the UK and concurrently changed its name to Zambia. The Southern Rhodesian colonial government in Salisbury felt that in the absence of a "Northern" Rhodesia, the continued use of "Southern" was superfluous. It passed legislation to become simply Rhodesia, but the British government refused to approve this on the grounds that the country's name was defined by British legislation, so could not be altered by the colonial government. Salisbury went on using the shortened name in an official manner nevertheless, while the British government continued referring to the country as Southern Rhodesia. This situation continued throughout the UDI period.
Thyroid Stimulating Hormone (TSH) (University of Washington Medical Center). September 2011. Method: Access 2 (Beckman Coulter). Thyroid Stimulating Hormone (TSH) (Collaborative Laboratory Services). September 2011. Method: Access 2 (Beckman Coulter). Thyroid Stimulating Hormone (TSH). September 2009. Method: Access 2 (Beckman Coulter). Lab 18 Thyroid Stimulating Hormone. 2001-2002. Method: Microparticle Enzyme Immunoassay. Lab 18 TSH - Thyroid Stimulating Hormone. 1999-2000. Method: Microparticle Enzyme Immunoassay.
=== Documentaries === Hofmann's Potion Archived June 16, 2021, at the Wayback Machine a documentary on the origins of LSD, 2002 Inside LSD National Geographic Channel, 2009 How to Change Your Mind Archived June 16, 2022, at the Wayback Machine Netflix docuseries, 2022
Sources: en.wikipedia.org
=== Plasma fractionation and Wiener directorship === In 1952, operation commenced plasma fractionation. Thereafter the range of antivenoms increased, including those against other snake species such as death adder (Acanthophis antarcticus) and the taipan (Oxyuranus scutellatus), plus spiders including the redback (Latrodectus hasselti) and – after much difficulty – the Sydney funnel-web (Atrax robustus). Much of this work, including the introduction in 1962 of a polyvalent antivenom against all of the major terrestrial Australian snakes, occurred under the direction of Saul Wiener, while from 1966 until the mid-1990s, venom research was coordinated by the eccentric but dedicated Struan Sutherland, who in 1979 released new guidelines for snakebite first aid, and a new test for snakebites that would identify which snake had envenomated the victim. Other major achievements of CSL include:
== External links == Media related to Ayahuasca at Wikimedia Commons The dictionary definition of ayahuasca at Wiktionary Ayahuasca - PsychonautWiki Ayahuasca - Erowid What is Ayahuasca? - Tripsitter The Ayahuasca Experience: A Pilgrimage to the Spirit - Double Blind Magazine
rhEPO has been used illicitly as a performance-enhancing drug. It can often be detected in blood, due to slight differences from the endogenous protein; for example, in features of posttranslational modification.
=== Depression === The evidence overall supports the effectiveness of bupropion over placebo for the treatment of depression. Evidence-based guidelines consistently recommend bupropion as a treatment option for adults with major depressive disorder; some support first-line use for major depressive disorder, but there is limited guidance for treatment-resistant depression. Some peer-reviewed studies suggest the quality of evidence is low. Some meta-analyses report that bupropion has an at-most small effect size for depression. Evidence suggests that the effectiveness of bupropion for depression is similar to that of other antidepressants. Over the autumn and winter months, bupropion can prevent the development of depression in those who have recurring seasonal affective disorder: 15% of participants on bupropion experienced a major depressive episode vs. 27% of those on placebo. Bupropion also improves depression in bipolar disorder, however the risk of an affective switch is similar to other antidepressants. Bupropion has several features that distinguish it from other antidepressants: for instance, unlike the majority of antidepressants, it does not usually cause sexual dysfunction, and the occurrence of sexual side effects is not different from placebo. Bupropion treatment is not associated with weight gain; on the contrary, the majority of studies observed significant weight loss in bupropion-treated participants. Bupropion treatment also is not associated with the sleepiness that may be produced by other antidepressants.
Sources: en.wikipedia.org
It corresponds to the first 28 amino acids of thymosin beta-4, a larger protein found in many tissues. The fragment is acetylated at its N-terminus and is produced synthetically for research and pharmaceutical use. Synthetic and natural forms share the same sequence.
It is usually described as an immunomodulatory peptide rather than a classical hormone. It does not travel to a single distant organ in the manner of an endocrine hormone. Classification varies across sources, and some texts group it with thymic peptides generally.
The broad outline involves immune cell activation, but the specific molecular steps remain under investigation. Different studies report effects on dendritic cells, T cells, and natural killer cells. No single receptor has been confirmed as the sole mediator.
Reverse-phase HPLC with ultraviolet detection at 214 nm is common. Mass spectrometry is used to confirm molecular identity and detect modifications. Immunoassays exist but may not distinguish the intact peptide from fragments.